Trial reportIndian journal of pediatrics2026
Oral Melatonin Supplementation for Sleep Disturbances in Children with Cerebral Palsy: A Randomized Double-Blind Controlled Trial.
Trial report in Indian journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Melatonin beyond chronobiology: integrating pharmacokinetics, dose-exposure forecasting, and clinical evidence.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo assess the efficacy and safety of oral melatonin in treating sleep problems in children with cerebral palsy (CP).
methodsA randomized, double-blind, placebo-controlled trial was conducted at a tertiary care government hospital in 120 children with CP (3 to 12 y) suffering from sleep problems and who failed to respond to non-pharmacological therapy (4 wk). Participants were randomized to receive oral melatonin (3 mg escalated to 10 mg)/ placebo for 12 wk. Sleep measures included the Sleep Disturbance Scale for Children (SDSC), and caregivers reported sleep and nap diaries (SND). Outcome measures included decreased sleep onset latency (SOL) and increased total sleep time (TST) calculated using sleep diaries at 4 and 12 wk.
resultsThe mean (SD) total sleep time in the melatonin and placebo groups was 5.09 (0.76) vs. 4.90 (0.77) h [Mean difference (MD) 0.19; P = 0.17] at baseline; 5.66 (0.84) vs. 4.89 (0.83) h (MD 0.77; P < 0.001) at 4 wk; 6.29 (0.78) vs. 4.98 (0.85) h (MD 1.31; P < 0.001) at 12 wk, respectively. The mean (SD) sleep onset time in melatonin and placebo groups was 79.18 ± 17.89 vs. 76.78 ± 13.60 min (MD 2.4; P = 0.41) at baseline; 63.70 ± 16.63 vs. 72.89 ± 15.38 min (MD 9.19; P < 0.003) at 4 wk; 43.20 ± 15.57 vs. 70.92 ± 14.95 min (MD 27.72; P < 0.001) at 12 wk, respectively. Melatonin was well tolerated with minimal side effects (n = 10).
conclusionsMelatonin, at a dose range of 3-10 mg once daily can significantly reduce SOL and improve TST in children with CP who have sleep problems with minimal adverse effects.
Indexed as
Identifiers
41369870What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.